Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Gain Therapeutics Inc

GANX ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.78

▲ +3.49%

Market Cap $77.69M · Vol 56.19K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$77.69M

Micro Cap

Div Yield

N/A

EPS Growth

+17.21%

YoY

RSI (14)

43.14

Momentum

Beta

0.19

vs Market

52W High

$4.34

60.37% below

52W Low

$1.54

11.69% above

Volume

56.19K

Avg 83.07K

P/B

7.30

Price-to-book

ROE

N/A

Return on equity

Free Float

97.77%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Gain Therapeutics Inc (GANX) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GANX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.09%

-12.75%

+0.00%

-32.06%

YTD

-44.72%

+12.66%

-51.89%

-77.58%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-20,161,100.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-110.47% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	7.30
P/FCF	N/A
EPS Growth	+17.21%
Outstanding Shares	43.64M

Technical Indicators

50-Day SMA	$1.83
200-Day SMA	$2.12
RSI (14)	43.14
Beta	0.19
52-Week High	$4.34
52-Week Low	$1.54

Volume Today	56.19K
Avg Daily Volume (30D)	83.07K
Relative Volume	0.68x
Volatility (10D)	40.70
Volatility (30D)	61.15
Free Float	97.77%

Analyst Consensus

BUY

Current Price $1.78

Mean Target $7.20

52W Low$1.54 52W High$4.34

Current

Target

$1.54 $4.34

Current Analyst target

+304.49% upside potential · 5 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00W7D7CK7

ISINUS36269B1052

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.23% ONC BeOne Medicines AG +1.55% 068270.KS Celltrion, Inc. +1.75% ABVX Abivax SA +4.66% ABVX.PA Abivax SA +3.59%

Company Profile

Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.